Lilly chooses another Corcept compound to combat Zyprexa weight gain
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly will fund studies to test effectiveness of Corcept Therapeutics' cortisol receptor antagonist CORT-108297 in rat models of olanzapine-induced weight gain, Corcept says Sept. 3. Corlux (mifepristone), Corcept's antipsychotic cortisol receptor antagonist also funded in part by Lilly, has reduced and mitigated weight gain associated with olanzapine (Lilly's atypical antipsychotic Zyprexa), but is more commonly known for its anti-progestational abortifacient properties (1Pharmaceutical Approvals Monthly September 2004, p. 14). CORT-108297 does not have Corlux's potent affinity for the PR receptor
You may also be interested in...
Corcept Beginning Mifepristone Pivotal Trials For Psychotic Depression
Corcept will begin the first of two pivotal Phase III trials for Corlux (mifepristone) for treatment of psychotic features of psychotic major depression "immediately," the firm said.
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.